Mega Lifesciences reports profit growth for Mega Lifesciences stock

Published on 10/14/2026 at 05:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Reported net profit grew 33.1 percent in the first half of 2026. Mega Lifesciences stock has a THB 29.0 billion market value.

Profit growth and reporting date

Reported net profit grew 33.1 percent in the first half of 2026.
Operating revenue increased 12.5 percent in the first half of 2026.
Mega Lifesciences stock stood at THB 33.25 on October 14, 2026.
The company scheduled its third-quarter earnings announcement for November 12, 2026.

Mega, TH0765010002, Illustration mit AI erstellt.

Mega Lifesciences (ISIN TH0765010002) reported 33.1 percent growth in net profit for the first half of 2026, while operating revenue increased 12.5 percent. The results put earnings quality and the November reporting date at the center of the stock story.

First-half growth broadens

According to Mega Lifesciences, operating revenue grew 12.5 percent year over year in the first half of 2026. Gross profit represented 52.0 percent of operating revenue, giving investors a second measure of the period's performance.

The company also reported EBITDA growth of 33.8 percent and adjusted net profit growth of 11.7 percent for the first half of 2026, alongside the 33.1 percent increase in reported net profit. The gap between reported and adjusted profit growth makes the quality of earnings an important comparison for the next report.

What does November add?

Mega Lifesciences lists November 12, 2026 as the date for its third-quarter 2026 earnings announcement, followed by an earnings conference call on November 13, 2026. The calendar gives the market a concrete checkpoint for testing whether the first-half growth rates continue.

For additional valuation context, Simply Wall St describes Mega Lifesciences as a SET-listed company and cites a market capitalization of THB 30.30 billion in September 2026. Its analysis also reports second-quarter 2026 net income of THB 514.61 million, up from THB 390.92 million a year earlier, while revenue rose to THB 3.62 billion from THB 3.44 billion.

Stock valuation and next date

Mega Lifesciences stock was quoted at THB 33.25 on the SET at 11:08 a.m. ICT on October 14, 2026, with a 52-week range of THB 27.75 to THB 40.00 and a market capitalization of THB 29.0 billion. The price stood 16.88 percent below the 52-week high, calculated from the same quote.

The combination of 12.5 percent revenue growth, 33.8 percent EBITDA growth and the November 12 reporting date gives the stock a clear numerical framework. The third-quarter update will show whether reported profit growth is translating into recurring operating momentum.